Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18038711 | 0.91 | NR1H2 (0.43) | NR1H2CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL25409415 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL994561 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL1979623 | 0.87 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL400513 | 0.86 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL608991 | 0.86 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL22169156 | 0.86 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL24884312 | 0.86 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| Hydrochloric Acid SCHEMBL7149386 | 0.84 | NR1H2 (0.49) | NR1H2CHRNB2CHRNA4CHRNA3USP2 | |
| SCHEMBL5242607 | 0.83 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA4CHRNA3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115286637-B | Triazabridged ring compounds, intermediate compounds thereof, preparation method and application | 成都金博汇康医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115286637-A | Triaza-bridged ring compound and intermediate compound, preparation method and application thereof | 成都金博汇康医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022194191-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12D | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-09-22 | — | — | WO | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | NR1H2 140/4885CHRNB2 1716/4885CHRNA4 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.